CG Oncology, Inc. Common stock (CGON) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
CGON Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, CG Oncology, Inc. Common stock (CGON) trades at a price-to-earnings ratio of -33.3x, with a stock price of $69.18 and trailing twelve-month earnings per share of $-2.08.
Compared to the Healthcare sector median P/E of 22.3x, CGON trades at a 249% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CGON trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CGON DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CGON P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $421M | 9.0Lowest | 5.17Best | -19% | |
| $7B | 15.5 | - | +1747%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See CGON's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGON Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGON vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGON — Frequently Asked Questions
Quick answers to the most common questions about buying CGON stock.
Is CGON stock overvalued or undervalued?
CGON current P/E: -33.3x. 5-year average P/E: N/A. Percentile: N/A.
How does CGON's valuation compare to peers?
CG Oncology, Inc. Common stock P/E of -33.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CGON's PEG ratio?
CGON PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.